Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARCT vs VNDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARCT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–4 Matrix Metrics)

ARCT Overall Winner 6-Pillar Tally: ARCT 3 – 2 VNDA (1 Tie) Matrix Metrics: ARCT 5 – 4 VNDA

As of Nov 16, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ARCT carries a Unified Composite Score of 57.7/100 (HOLD) at $8.43 (2.5x Forward P/E, -311.2% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin).

  • Growth vs. Quality Trade-Off: ARCT earns the overall head-to-head edge with a stronger Unified Composite Score (57.7/100 HOLD vs. VNDA 49.0/100 HOLD) and 2.01β · 127% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ARCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARCT vs VNDA
ARCT NASDAQ Head-to-Head Winner
Arcturus Therapeutics Holdings Inc. Common Stock
Pharmaceutical Preparations
$8.43
+0.84% 1D
Market Cap $241.0M
TTM Revenue $31M
Forward P/E 2.5x
Beta / 30D Vol 2.01β · 127% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 39
RSI-14: 39.1 · SMA20: $10.11 · SMA50: $12.28
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (ARCT 3 – 2 VNDA)

Columns: Metric · ARCT · VNDA
1. Valuation Multiples ARCT
Forward P/E 2.5x 103.1x
Trailing P/E 2.5x 103.1x
PEG Ratio N/M 2.23x
EV / Revenue 2.6x 0.9x
2. Growth & Scale VNDA
Revenue Growth (YoY) +6.7% +24.1%
Earnings Growth (YoY) +0.0% -95.9%
TTM Revenue (USD) $31M $229M
Market Cap $241.0M $238.9M
3. Profitability & Quality VNDA
Gross Margin N/A 93.6%
Operating Margin -311.2% -77.6%
Net Profit Margin -285.9% -119.9%
Return on Equity (ROE) -44.4% -82.5%
4. Balance Sheet & Cash Flow ARCT
Cash Generation (TTM) -$62M -$150M
Cash Flow Margin N/A -65.4%
Net Cash / Leverage $163M Net Cash $40M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARCT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 81.0% (4th %ile) 163.3% (75th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARCT (5) vs VNDA (4)
Institutional Metric ARCT VNDA Criterion Row Edge
Market Capitalization
Scale
$241.0M $238.9M Larger Scale Tie
Trailing P/E Ratio
Valuation
2.5x 103.1x Lower Multiple ARCT
Forward P/E Ratio
Valuation
2.5x 103.1x Lower Multiple ARCT
Revenue Growth (YoY)
Growth
+6.7% +24.1% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-311.2% -77.6% Higher Margin VNDA
Net Profit Margin
Profitability
-285.9% -119.9% Higher Margin VNDA
Return on Equity (ROE)
Capital Efficiency
-44.4% -82.5% Higher ROE ARCT
52-Week Range Position
Momentum
24% ($6–$18) 4% ($4–$10) Stronger Trend ARCT
Beta / 30D Volatility
Risk Regime
2.01β · 127% Vol 1.25β · 61% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
57.7 / 100 (HOLD) 49.0 / 100 (HOLD) Higher Composite ARCT
Trailing 12M Revenue (USD)
Operating Scale
$31M $229M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 93.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev 2.23x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$62M ($163M Net Cash) -$150M ($40M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VNDA +12.64 pp
ARCT: -18.47% · VNDA: -5.83%
3M Horizon ARCT +32.92 pp
ARCT: +2.68% · VNDA: -30.24%
6M Horizon ARCT +57.49 pp
ARCT: +19.91% · VNDA: -37.58%
1Y Horizon ARCT +21.05 pp
ARCT: +8.49% · VNDA: -12.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARCT Revenue VNDA Revenue ARCT Op. Margin VNDA Op. Margin Margin Leader
FY2018 $20M $190M -138.5% 11.3% VNDA
FY2019 $20M $230M -122.7% 10.0% VNDA
FY2020 $10M $250M -749.8% 11.0% VNDA
FY2021 $10M $270M -1641.3% 15.7% VNDA
FY2022 $210M $250M 5.9% 2.5% ARCT
FY2023 $170M $190M -46.9% -7.2% VNDA
FY2024 $150M $200M -62.8% -20.5% VNDA
FY2025 $80M $220M -93.0% -70.0% VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARCT BREAKDOWN
42d in phase · OBV DISTRIBUTION
Current IV 81.0%
IV Percentile 4th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARCT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $241.0M market capitalization and -311.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARCT vs VNDA Key Questions & Quantitative Answers

As of Nov 16, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ARCT carries a Unified Composite Score of 57.7/100 (HOLD) at $8.43 (2.5x Forward P/E, -311.2% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin). Growth vs. Quality Trade-Off: ARCT earns the overall head-to-head edge with a stronger Unified Composite Score (57.7/100 HOLD vs. VNDA 49.0/100 HOLD) and 2.01β · 127% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ARCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: ARCT posts +6.7% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (N/A gross margin, -311.2% operating margin), compared with VNDA at +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARCT cumulative revenue shifted +300.0% while VNDA shifted +15.8%. In operating R&D and SG&A reinvestment, ARCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VNDA.

ARCT screens cheaper on headline valuation multiples. ARCT trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin), whereas VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARCT (-44.4% ROE) versus VNDA (-82.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ARCT carries 81.0% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 127% Vol realized risk). By comparison, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.